Skip to main content

Table 1 Patient characteristics

From: Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: a retrospective clinical study

Item CHIP group
(n = 22)
IV group
(n = 21)
P value
Age (years), median 51 (38–69) 55 (43–68) 0.552
Sex    0.586
Male 14 15  
Female 8 6  
Comorbidities
 Hypertension 10 6 0.252
 Hepatitis B 2 2 1
 Diabetes 2 2 1
 Chronic pulmonary disease 3 4 0.689
 Poststroke 1 0  
 Coronary heart disease 1 1  
Pathological type    0.804
 Adenocarcinoma 14 15  
 Signet ring cell carcinoma 6 5  
 Mucinous adenocarcinoma 2 1  
Stage    0.876
 II 4 5  
 IIIA 9 8  
 IIIB 6 4  
 IIIC 3 4  
MMR status    0.729
 dMMR 4 3  
 pMMR 18 18  
Surgery mode    0.658
 Subtotal gastrectomy 13 11  
 Total gastrectomy 9 10  
  1. CHIP chemotherapeutic hyperthermic intraperitoneal perfusion; IV chemotherapy alone; dMMR deficient mismatch repair; pMMR proficient mismatch repair